[ad_1]
In standard published on your portal, the General Directorate of Health indicates, however, that “In no case should vaccination of a person aged 65 years or older be delayed”, if only the vaccine in question is available.
The General Directorate of Health also indicates the vaccination schedule for Vaccine AstraZeneca, in which it recommends “two doses with an interval of 12 weeks.”
However, if SARS-CoV-2 infection is confirmed after the first dose, “the second dose should not be given.” Also, the second dose is not recommended for anyone who has been infected.
“All vaccination opportunities must be taken advantage of to complete the vaccination schedule, respecting the recommendations of this standard.”
There are no data yet on the administration of the vaccine to pregnant women and it is unknown whether the vaccine is “excreted in human milk.”
People with symptoms suggesting Covid-19 should not be vaccinated without excluding SARS-CoV-2 infection“, AND” people in prophylactic isolation should postpone vaccination until completion. ”
“Vaccination of people with severe acute illness, with or without fever, must wait until full recovery., with the main objective of avoiding the overlap of the symptoms of the disease with possible adverse effects to vaccination ”
The interaction of AstraZeneca vaccine with other vaccines has not yet been studied.. “Given that it is a new vaccine, and also to allow the assessment of possible adverse effects, the administration of this vaccine should, whenever possible, respect an interval of 2 weeks in relation to the administration of other vaccines. However, if this implies a risk of non-vaccination, it should not be postponed ”.
At the time of inoculation, “the information on the vaccines administered in the previous two weeks must be verified in the individual vaccination registry (VACINAS Platform)”.
The clinical trials of the vaccine “included people with comorbidities, such as obesity (BMI ≥30.0 kg / m2), cardiovascular disease, respiratory disease, diabetes: the efficacy was similar in participants with and without one or more of these comorbidities”
In people with autoimmune or autoinflammatory diseases, “there is no evidence that vaccination causes exacerbation or precipitates an acute crisis.”
The act of inoculation “must always be preceded by questions aimed at detecting possible contraindications or precautions related to the vaccine to be administered.”
The most common adverse reactions are mild or moderate in intensity and resolve within a few days after vaccination.
Very common adverse effects were “tenderness, pain, warmth, itching or bruising at the injection site, fatigue, malaise, myalgia, arthralgia; fever (<38ºC), chills, headache, nausea ”.
The personnel who administer the vaccine have the obligation to “clarify in advance, clearly, the vaccine to be administered, explaining the benefits of vaccination and possible adverse reactions, as well as the risk of non-vaccination, where appropriate.
“All vaccination acts must be registered promptly (maximum period of 24 hours) registered in the National Platform for Vaccine Registration and Management – VACCINES, in the Individual Health Bulletin and, where appropriate, in the vaccination card that is delivery with the vaccine “, adds the standard that” will be updated according to the information that is available. ”
